NorthWest Biotherapeutics Inc (NWBO)

[HappyLibrarian]

I can say it just fine.

I have always said there might be issues with the Phase 3 trial despite the fact that L has good science and of course have been frustrated that the failure to finish L has kept Direct stalled without starting Phase 2 for years.

There is nothing new and you should not confuse the Phase 3 trial with the science itself.

In fact one of the reasons I briefly got suckered into getting excited this time last year was that the acceptance of the endpoint changes seemed to address a lot of those issues with the trial and that, along with the seeming advent of TLD made me feel pretty good that NWBO was finally moving in a much better direction,.

But after another year of no solid news on the core issues besides data lock (which was assumed anyway by a September 2020 date for TLD) I believe that NWBO management is acting like the results are not good despite the endpoint changes (I do not accept that a good PR operation could not deal with Mr. Feurstein better than silence and we will never agree on that point).

Also, you got met thinking: Do we know for a fact that the FDA has accepted those endpoint changes? To my knowledge we only know about Europe and are making big assumptions (which would be all our fault and no fault of NWBO's) in thinking that they are accepted on both sides of the Atlantic.

I have spent too long to quit now and want to have all my shares there for the band-aid rip-off but prudent shareholders have to be mentally prepared for more TLD delays and for TLD to be a bit of a let down and for approval to be no sure thing even if it still very likely because there are no treatments for GBM. But this talk of L being used for all cancers etc. is a bit much.